IL-13 Antibody, anti-human

Name: IL-13 Antibody, anti-human
Availability: InStock

IL-13 Antibody, anti-humanExtended Validation

Clone:

JES10-5A2.2

Type of antibody:

Primary antibodies, Functional-grade antibodies

Isotype:

rat IgG1, rat IgG1κ

Applications:

FA, ICFC

Alternative names:

P600

Intracellular flow cytometry applications forIL-13 Antibody, anti-human

PE
Vio R667

Conjugate:

PE

Recommended dilution:

1:50

Remark:

The antibody is suited for staining of formaldehyde-fixed cells.

Tested:

QC tested

Products used:

130-128-304, 130-128-212

Protocols:

Intracellular flow cytometry staining protocol (Inside Stain Kit 1:50)

Description:

Human peripheral blood mononuclear cells (PBMCs) were either left unstimulated (left image) or stimulated with CytoStim for 6 hours. After 2 hours, brefeldin A was added. Cells were fixed, permeabilized, and stained with Anti-IL-13 antibodies and CD154 antibodies. Cells were analyzed by flow cytometry. Plots show CD4⁺ lymphocytes gated according to CD4-FITC staining.

Functional assay applications forIL-13 Antibody, anti-human

pure-functional grade

Conjugate:

pure-functional grade

Tested:

during development

Products used:

130-096-210

Type of functional assay:

neutralization of cytokine activity

Extended validation for IL-13 Antibody, anti-human

Specificity

Epitope competition

In order to compare the epitope specificity of an antibody, the clone being used is compared with other known clones recognizing the same antigen in a competition assay.

Other clones	Overlap in epitope recognition with JES10-5A2.2
REA1011	++
85BRD	+
32007	+
B69-2	+
Cells were incubated with an excess of purified unconjugated IL-13 (JES10-5A2.2) antibody followed by staining with fluorochrome-conjugated antibodies of other known clones against the same marker. Based on the fluorescence signal obtained, the clones were identified as recognizing completely overlapping (++), partially overlapping (+), or completely different epitopes (-) of the marker.

Sensitivity

Performance comparison

Selected fluorochrome conjugated antibodies from Miltenyi Biotec were compared to commercially available hybridoma clones in flow cytometry analysis.

Flow cytometric comparison of different clones for IL-13. Human peripheral blood mononuclear cells (PBMCs) were stimulated with 20 ng/mL Phorbol 12-myristate 13-acetate (PMA) and 1 µg/ml Ionomycin for 1 hour, followed by an incubation with 1µg/mL Brefeldin A for 5 hours. Cells were first stained with Viobility™ Fixable Dye followed by a suitable counterstaining. Cells were then fixed and permeabilized using the Inside Stain Kit followed by a staining with IL-13 antibodies. As a control, IL-13 antibody staining was omitted and cells were measured in the same channels. Flow cytometry was performed with the MACSQuant^® Analyzer. CD4⁺ cells were pregated for the analysis. Cell debris, dead cells, and cell doublets were excluded from the analysis based on scatter signals and Viobility 405/520 Fixable Dye fluorescence. No FcR Blocking Reagent was used. The recommended titers of respective antibodies from different suppliers were used.

Flow cytometric comparison of different clones for IL-13. Human peripheral blood mononuclear cells (PBMCs) were stimulated with 20 ng/mL Phorbol 12-myristate 13-acetate (PMA) and 1 µg/ml Ionomycin for 1 hour, followed by an incubation with 1µg/mL Brefeldin A for 5 hours. Cells were first stained with Viobility™ Fixable Dye followed by a suitable counterstaining. Cells were then fixed and permeabilized using the Inside Stain Kit followed by a staining with IL-13 antibodies. As a control, IL-13 antibody staining was omitted and cells were measured in the same channels. Flow cytometry was performed with the MACSQuant^® Analyzer. CD4⁺ cells were pregated for the analysis. Cell debris, dead cells, and cell doublets were excluded from the analysis based on scatter signals and Viobility 405/520 Fixable Dye fluorescence. No FcR Blocking Reagent was used. The recommended titers of respective antibodies from different suppliers were used.

Flow cytometric comparison of different clones for IL-13. Human peripheral blood mononuclear cells (PBMCs) were stimulated with 20 ng/mL Phorbol 12-myristate 13-acetate (PMA) and 1 µg/ml Ionomycin for 1 hour, followed by an incubation with 1µg/mL Brefeldin A for 5 hours. Cells were first stained with Viobility™ Fixable Dye followed by a suitable counterstaining. Cells were then fixed and permeabilized using the Inside Stain Kit followed by a staining with IL-13 antibodies. As a control, IL-13 antibody staining was omitted and cells were measured in the same channels. Flow cytometry was performed with the MACSQuant^® Analyzer. CD4⁺ cells were pregated for the analysis. Cell debris, dead cells, and cell doublets were excluded from the analysis based on scatter signals and Viobility 405/520 Fixable Dye fluorescence. No FcR Blocking Reagent was used. The recommended titers of respective antibodies from different suppliers were used.

Flow cytometric comparison of different clones for IL-13. Human peripheral blood mononuclear cells (PBMCs) were stimulated with 20 ng/mL Phorbol 12-myristate 13-acetate (PMA) and 1 µg/ml Ionomycin for 1 hour, followed by an incubation with 1µg/mL Brefeldin A for 5 hours. Cells were first stained with Viobility™ Fixable Dye followed by a suitable counterstaining. Cells were then fixed and permeabilized using the Inside Stain Kit followed by a staining with IL-13 antibodies. As a control, IL-13 antibody staining was omitted and cells were measured in the same channels. Flow cytometry was performed with the MACSQuant^® Analyzer. CD4⁺ cells were pregated for the analysis. Cell debris, dead cells, and cell doublets were excluded from the analysis based on scatter signals and Viobility 405/520 Fixable Dye fluorescence. No FcR Blocking Reagent was used. The recommended titers of respective antibodies from different suppliers were used.

Flow cytometric comparison of different clones for IL-13. Human peripheral blood mononuclear cells (PBMCs) were stimulated with 20 ng/mL Phorbol 12-myristate 13-acetate (PMA) and 1 µg/ml Ionomycin for 1 hour, followed by an incubation with 1µg/mL Brefeldin A for 5 hours. Cells were first stained with Viobility™ Fixable Dye followed by a suitable counterstaining. Cells were then fixed and permeabilized using the Inside Stain Kit followed by a staining with IL-13 antibodies. As a control, IL-13 antibody staining was omitted and cells were measured in the same channels. Flow cytometry was performed with the MACSQuant^® Analyzer. CD4⁺ cells were pregated for the analysis. Cell debris, dead cells, and cell doublets were excluded from the analysis based on scatter signals and Viobility 405/520 Fixable Dye fluorescence. No FcR Blocking Reagent was used. The recommended titers of respective antibodies from different suppliers were used.

Specifications for IL-13 Antibody, anti-human

Overview

Interleukin-13 (IL-13) is produced primarily by activated Tʜ2 cells, but also by mast cells, NK cells, and dendritic cells. IL-13 exerts anti-inflammatory effects on monocytes and macrophages. Furthermore, it inhibits the expression of pro-inflammatory cytokines, such as IL-1β, TNF-α, IL-6, and IL-8. IL-13 has also been shown to enhance B cell proliferation and to induce isotype switching, resulting in an increased production of IgE.

IL-13, in contrast to IL-4, fails to induce Tʜ2 cell differentiation, one of the hallmarks of the allergic response.

Alternative names

P600

Detailed product information

Technical specifications

Clone	JES10-5A2.2
Clonality	monoclonal
Isotype	rat IgG1κ, rat IgG1
Isotype control	Isotype Control Antibody, rat IgG1
Host	rat
Type of antibody	Primary antibodies, Functional-grade antibodies
Species	human, non-human primate
Cross-reactivity	rhesus monkey ( Macaca mulatta )
Antigen	IL-13
Alternative names of antigen	P600
Molecular mass of antigen [kDa]	13
Entrez Gene ID	3596
RRID	AB_2660007, AB_2660008, AB_2905282, AB_2905281, AB_10827597

Resources for IL-13 Antibody, anti-human

Certificates

Please follow this

link

to search for Certificates of Analysis (CoA) by lot number.

References for IL-13 Antibody, anti-human

Publications

Wynn, T. (2003) IL-13 effector functions. Annu. Rev. Immunol. 21: 425-456

Applications

Extended validation